William Blair Analysts Increase Earnings Estimates for TMDX

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair increased their Q3 2025 EPS estimates for TransMedics Group in a research report issued to clients and investors on Tuesday, December 10th. William Blair analyst R. Daniels now anticipates that the company will post earnings per share of $0.43 for the quarter, up from their prior estimate of $0.42. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group’s Q4 2025 earnings at $0.49 EPS.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 63.7% on a year-over-year basis.

Several other research analysts have also recently weighed in on the stock. TD Cowen decreased their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Piper Sandler lowered their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. cut their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $126.80.

TransMedics Group Price Performance

TransMedics Group stock opened at $64.26 on Friday. The business has a 50-day simple moving average of $95.77 and a 200 day simple moving average of $131.45. TransMedics Group has a 52 week low of $63.42 and a 52 week high of $177.37. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of 68.36 and a beta of 2.06. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in the company. Driehaus Capital Management LLC raised its stake in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Geode Capital Management LLC raised its position in TransMedics Group by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after buying an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,042 shares of company stock valued at $3,563,985 over the last ninety days. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.